The economic consequences of prostate and bladder cancer in the UK

BJU International

Volumn 95, Issue 1, 2005, Pages 59-63

  Sangar, Vijay K ^a   Ragavan, Narasimhan ^a,b   Matanhelia, Shyam S ^a   Watson, Mike W ^a   Blades, Rosie A ^a  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Direct costs; Indirect costs; Prostate cancer; Research fund allocation; Total costs

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; DATA BASE; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NATIONAL HEALTH SERVICE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RESOURCE ALLOCATION; TRANSURETHRAL RESECTION; UNITED KINGDOM; CANCER RESEARCH; COST OF ILLNESS; FEMALE; HEALTH CARE ORGANIZATION;

ADOLESCENT; ADULT; AGED; BIOMEDICAL RESEARCH; COSTS AND COST ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH EXPENDITURES; HUMANS; INCOME; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RESEARCH SUPPORT; URINARY BLADDER NEOPLASMS;

EID: 12544256265     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05249.x     Document Type: Article

References (18)

1. Office of National Statistics. Series MB1 no. 30. Registration of cancer diagnosed in England. London: Her Majesty's Stationary Office, 1999
2. Office of National Statistics. Series MB1. No. 28. Registrations of Cancer Diagnosed in 1995-97 in England. London: Her Majesty's Stationary Office, 1997
3. Offices for National Statistics. Series DH2. No 23. Mortality Statistics by Cause. England and Wales 1996. London: Her Majesty's Stationary Office, 1996
4. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8
5. Soloway MS. Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 1980; 123: 461-6
6. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7
7. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment Panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997; 79 (Suppl. 3)
8. BAUS. Analyses of minimum data set for urological cancers. London: BAUS Section of Oncology, October 2002
9. Aus G, Abbou CC, Heidenreich A et al. Guidelines on Prostate Cancer. European Association of Urology. Update. Arnhem, the Netherlands. Drukkerij Gelderland Bv, 2003
10. Oostelinck W, Lobel B, Jaske G, Malmstrom P-U, Stockle M, Sternberg C. Guidelines on Bladder Cancer. European Association of Urology. Arnhem, The Netherlands: Drukkerij Gelderland bv, 2002
11. UK Economics Database. Statistics for Education, Bishops Stortford, UK, 2002
12. NCRI. Strategic analyses 2002. An Overview of Cancer Research in the UK. Directly Funded by the NCRI Partner Organisations. London: National Cancer Research Institute, October 2002 http:// www.ncri.org.uk/documents/publications/ reportdocs/NCRI_Strategic_Analysis_.pdf
13. Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol 2000; 164: 735-7
14. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92: 1731-9
15. Potosky AL, Knopf K, Clegg LX et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-7
16. Nygard R, Norum J, Due J. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 2001; 21: 781-8
17. Burkhardt JH, Litwin MS, Rose CM et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002; 20: 2869-75
18. Hedelin H, Holmang S, Wiman L. The cost of bladder tumor treatment and follow-up. Scand J Urol Nephrol 2002; 36: 344-7